Andecaliximab

Product Name: Andecaliximab
CAS No.: 1518996-49-0
Chemical Name: Andecaliximab
Synonyms: GS-5745;Andecaliximab;Research Grade Andecaliximab;Research Grade Andecaliximab(DHD06801)
CBNumber: CB68080925
Formula Weight: 0
MOL File: Mol file

More

Less

Andecaliximab Property

form: Liquid
color: Colorless to light yellow

More

Less

Hazard and Precautionary Statements (GHS)

More

Less

Andecaliximab Chemical Properties,Usage,Production

Uses

Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF)[1][2].

in vivo

Andecaliximab improves T-cell receptor (TCR) diversity (decreased clonality) within tumor-infiltrating T-cell^[1]. Andecaliximab (20 mg/kg; i.p. once) shows the antifibrotic efficacy in a humanized NSG mouse model of idiopathic pulmonary fibrosis^[2].

Animal Model:	Humanized nonobese diabetic, SCID, IL-2 receptor g (NSG) mouse model of IPF^[2]
Dosage:	20 mg/kg
Administration:	Intraperitoneal injection; 20 mg/kg, once a week for once
Result:	Decreased SMAD2 phosphorylation and increased surfactant protein C. Reduced MMP9⁺ cells, including MMP9⁺, CCR10⁺ and MMP9⁺CD45^- and EpCAM⁺CCR10⁺ subpopulations.

References

[1] Andrew E. Greenstein, et al. Effect of andecaliximab (anti-MMP9) on proteolysis of IL-7 in vitro, TCR diversity in mice, and serum IL-7 in gastric cancer patients in combination with chemotherapy. 2018 ASCO-SITC Clinical Immuno-Oncology Symposium.
[2] Espindola MS, et al. Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021 Feb 15;203(4):458-470. DOI:10.1164/rccm.201910-1977OC

Andecaliximab Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

Andecaliximab Suppliers

China 18 Global 18

ShangHai Biochempartner Co.,Ltd

Tel: 177-54423994 17754423994
Fax: QQ:2853530913
Email: 2853530910@QQ.com
Country: China
ProdList: 8000
Advantage: 62

Guangzhou Hongyuan Chemical Co.,Ltd

Tel: 15817493340
Email: 981810490@qq.com
Country: China
ProdList: 1566
Advantage: 58

Wuhan Chemstan Biotechnology Co., Ltd.

Tel: 027-65317797 15926423062
Fax: QQ：422450190
Email: 422450190@qq.com
Country: China
ProdList: 10308
Advantage: 58

TargetMol Chemicals Inc.

Tel: 4008200310
Email: marketing@tsbiochem.com
Country: China
ProdList: 24961
Advantage: 58

Biolab Reagents

Tel: 027-65279366 18108604356
Email: products@biolabreagent.com
Country: China
ProdList: 9868
Advantage: 58

Wuhan Jingkangen Biomedical Technology Co., Ltd

Tel: 13720134139 086-15871494362 13720134139
Email: orders@jknbiochem.com
Country: China
ProdList: 6762
Advantage: 58

Shanghai Yifei Biotechnology Co. , Ltd.

Tel: 021-65675885 18964387627
Email: customer_service@efebio.com
Country: China
ProdList: 11973
Advantage: 58

Changsha Fuzhen Biotechnology Co.，LTD

Tel: 0731-13823398 15111215862
Email: 313359644@qq.com
Country: China
ProdList: 4161
Advantage: 58

Olix (Shanghai) Pharmaceutical Technology Co., Ltd

Tel: 17316404525 17316404525
Email: 209533805@qq.com
Country: China
ProdList: 9765
Advantage: 58

Wanxin Biotechnology (Jiaxing) Co., LTD

Tel: 0573-83568680 18057391398
Email: 3956524501@qq.com
Country: China
ProdList: 1442
Advantage: 58

1518996-49-0, AndecaliximabRelated Search:

Afasevikumab Evinacumab Tamrintamab Cetuximab Fletikumab Racotumomab Varisacumab Odesivimab tadocizumab Solanezumab

Andecaliximab

Research Grade Andecaliximab(DHD06801)

GS-5745

Research Grade Andecaliximab

1518996-49-0